Use of composition in preparing medicament for preventing and / or treating pulmonary disease
By activating or enhancing substances that enhance the IL-4/IL-4RA signaling pathway, regulating immune responses and inhibiting vascular remodeling, this technology solves the treatment challenges of pulmonary hypertension and other lung diseases in existing technologies, achieving significant reductions in pulmonary artery pressure and improvements in lung function.
Patent Information
- Application Number
- PCT/CN2025/107084
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2025-07-04
- Publication Date
- 2026-11-19
AI Technical Summary
While existing treatments for pulmonary arterial hypertension (PAH) can alleviate symptoms to some extent, they cannot fundamentally change the course of the disease, and long-term use may cause side effects. Existing technologies are also unable to effectively activate or enhance the IL-4/IL-4RA signaling pathway to treat lung diseases.
Lung diseases can be treated by using substances that can activate or enhance the IL-4/IL-4RA signaling pathway, such as IL-4 protein and IL-4 protein receptor agonists, to regulate immune responses, inhibit vascular remodeling, and improve lung function, including IL-4 fusion proteins and ligands of IL-4RA protein.
By activating or enhancing the IL-4/IL-4RA signaling pathway, it significantly reduces pulmonary artery pressure, decreases vascular remodeling, inhibits inflammatory responses, effectively prevents and treats pulmonary hypertension, idiopathic pulmonary fibrosis and asthma, and improves lung function.
Smart Images

Figure CN2025107084_19112026_PF_FP_ABST
Abstract
Description
Use of the composition in the preparation of medicaments for the prevention and / or treatment of lung diseases
[0001] Cross-references to related applications
[0002] This application claims priority to Chinese Patent Application No. 2025106036467, filed on May 12, 2025, entitled “Use of a composition in the preparation of a medicament for the prevention and / or treatment of lung diseases”, the entire contents of which are incorporated herein by reference. Technical Field
[0003] This application belongs to the field of biomedical technology, and in particular relates to the use of the composition in the preparation of medicaments for the prevention and / or treatment of lung diseases. Background Technology
[0004] Pulmonary hypertension (PAH) is a malignant pulmonary vascular disease with high morbidity and mortality. Clinically, it is classified into five categories, characterized by elevated pulmonary artery blood pressure, ultimately leading to right heart failure. The pathogenesis of PAH is complex, involving multiple aspects such as pulmonary vascular smooth muscle cell proliferation, endothelial dysfunction, and immune inflammatory responses. Current treatments mainly include vasodilators, endothelin receptor type A (RA) antagonists, and phosphodiesterase 5 inhibitors. These drugs can alleviate symptoms and improve hemodynamics to some extent, but they usually cannot fundamentally change the course of the disease, and long-term use may cause certain side effects. Summary of the Invention
[0005] This application provides an example of the use of a composition in the preparation of a medicament for the prevention and / or treatment of lung diseases, which can effectively treat lung diseases.
[0006] In a first aspect, this application provides the use of a composition in the preparation of a medicament for the prevention and / or treatment of lung diseases, the composition comprising a substance capable of activating or enhancing the IL-4 / IL-4RA signaling pathway; the lung diseases include pulmonary hypertension, idiopathic pulmonary fibrosis, and asthma.
[0007] In any embodiment of this application, the substance capable of activating or enhancing the IL-4 / IL-4RA signaling pathway includes at least one of the following: (1) IL-4 protein; (2) a substance that increases the activity and / or content of IL-4 protein; (3) a receptor agonist of IL-4 protein; (4) a substance that increases the activity and / or content of a receptor agonist of IL-4 protein.
[0008] In any embodiment of this application, the IL-4 protein includes at least one of the following: recombinant IL-4 protein, truncated IL-4 protein, mutant IL-4 protein, and fusion protein.
[0009] In any embodiment of this application, the IL-4 fusion protein includes at least one of IL-4-Fc fusion protein, IL-4-anti-inflammatory factor fusion protein, and IL-4-targeting peptide fusion protein.
[0010] In any embodiment of this application, the substance that enhances the activity and / or content of IL-4 protein includes at least one of the following: protein, antibody, antibody mimic, fusion protein, protein analog, gene delivery vector, protein delivery vector, polypeptide, peptide mimic, nucleic acid molecule, and small molecule compound.
[0011] In any embodiment of this application, the substance that enhances the activity and / or content of IL-4 protein includes at least one of gene delivery vectors, protein delivery vectors, nucleic acid molecules, proteins, and fusion proteins capable of enhancing the activity and / or content of IL-4 protein; optionally, the substance that enhances the activity and / or content of IL-4 protein includes at least one of the following: a vector expressing IL-4 protein, an mRNA nucleic acid molecule encoding IL-4 protein, lipid nanoparticles carrying the IL-4 gene, a viral vector carrying the IL-4 gene, a PEG-modified protein encapsulating the IL-4 gene or protein, a protein microsphere encapsulating the IL-4 gene or IL-4 protein, a liposome encapsulating the IL-4 gene or IL-4 protein, and an extracellular vesicle encapsulating the IL-4 gene or IL-4 protein; the viral vector includes at least one of adeno-associated virus vectors, adenovirus vectors, lentiviral vectors, retroviral vectors, poxvirus vectors, and herpesvirus vectors.
[0012] In any embodiment of this application, the receptor agonist of the IL-4 protein includes an agonist of the IL-4RA protein; the agonist of the IL-4RA protein includes at least one of the following: a ligand of the IL-4RA protein, a ligand of a truncated form of the IL-4RA protein, a ligand of a mutant form of the IL-4RA protein, and a ligand of an IL-4RA fusion protein; optionally, the agonist of the IL-4RA protein includes a ligand of the IL-4RA protein.
[0013] In any embodiment of this application, substances that enhance the receptor agonist activity and / or content of IL-4 protein include substances capable of enhancing the agonist activity and / or content of IL-4RA protein; optionally, substances that enhance the agonist activity and / or content of IL-4RA protein include at least one of proteins, antibodies, antibody mimics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, peptides, peptide mimics, nucleic acid molecules, and small molecule compounds capable of enhancing the ligand activity and / or content of IL-4RA protein; optionally, substances that enhance the agonist activity and / or content of IL-4RA protein include vectors expressing ligands of IL-4RA protein, m-type vectors encoding ligands of IL-4RA protein, etc. The viral vector comprises at least one of the following: RNA nucleic acid molecules, lipid nanoparticles carrying the ligand gene of IL-4RA protein, viral vectors carrying the ligand gene of IL-4RA protein, PEG-modified proteins encapsulating the ligand gene of IL-4RA protein or the ligand of IL-4RA protein, protein microspheres encapsulating the ligand gene of IL-4RA protein or the ligand of IL-4RA protein, liposomes encapsulating the ligand gene of IL-4RA protein or the ligand of IL-4RA protein, and extracellular vesicles encapsulating the ligand gene of IL-4RA protein or the ligand of IL-4RA protein; the viral vector comprises at least one of the following: adeno-associated virus vector, adenovirus vector, lentiviral vector, retroviral vector, poxvirus vector, and herpesvirus vector.
[0014] In any embodiment of this application, pulmonary hypertension includes at least one of arterial pulmonary hypertension, pulmonary hypertension caused by chronic obstructive pulmonary disease, and pulmonary hypertension caused by autoimmune disease-related pulmonary vascular disease; optionally, pulmonary hypertension caused by autoimmune disease-related pulmonary vascular disease includes lupus-related pulmonary hypertension.
[0015] In any embodiment of this application, the medicament further includes a pharmaceutically acceptable carrier, excipient, or salt; optionally, the dosage form of the medicament includes a gastrointestinal dosage form or a non-gastrointestinal dosage form; optionally, the route of administration of the medicament includes a gastrointestinal route or a non-gastrointestinal route. Beneficial effects
[0016] The use of the compositions of this application in the preparation of medicaments for the prevention and / or treatment of lung diseases, wherein the compositions include substances capable of activating or enhancing the IL-4 / IL-4RA signaling pathway, and the lung diseases include pulmonary hypertension, idiopathic pulmonary fibrosis and asthma, wherein by activating or enhancing the specific signaling pathway IL-4 / IL-4RA, pulmonary artery pressure can be significantly reduced, vascular remodeling can be reduced, and inflammatory responses can be inhibited, thereby effectively preventing and / or treating lung diseases. Attached Figure Description
[0017] To more clearly illustrate the technical solutions of the embodiments of this application, the accompanying drawings used in the embodiments of this application will be briefly introduced below. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0018] Figure 1 is a schematic diagram of the IL-4 level in the peripheral circulation of patients with pulmonary hypertension.
[0019] Figure 2 shows a schematic diagram of how IL-4 deficiency promotes pulmonary artery pressure and vascular remodeling in PAH mice. (Figure 2A is a statistical graph of right ventricular systolic pressure measured after the establishment of the four mouse models in Example 2; Figure 2B is a schematic diagram of the dynamic right ventricular pressure measured after the establishment of the four mouse models in Example 2; Figure 2C is a schematic diagram of the ratio of lung weight to body weight measured after the establishment of the four mouse models in Example 2; Figure 2D is a schematic diagram of the ratio of heart weight to body weight measured after the establishment of the four mouse models in Example 2; Figure 2E is a schematic diagram of the ratio of right ventricular weight to left ventricular weight (Hilton index) measured after the establishment of the four mouse models in Example 2; Figure 2F is a schematic diagram of pulmonary vascular remodeling detected by hematoxylin and eosin staining; Figure 2G is a schematic diagram of pulmonary vascular remodeling detected by Masson staining.)
[0020] Figure 3 shows a schematic diagram of how IL-4RA deficiency promotes pulmonary artery pressure and vascular remodeling in PAH mice (where Figure 3A is a statistical graph of right ventricular systolic pressure measured after the establishment of the four mouse models in Example 3; Figure 3B is a schematic diagram of the dynamic right ventricular pressure measured after the establishment of the four mouse models in Example 3; Figure 3C is a statistical graph of the ratio of lung weight to body weight measured after the establishment of the four mouse models in Example 3; Figure 3D is a schematic diagram of the ratio of heart weight to body weight measured after the establishment of the four mouse models in Example 3; Figure 3E is a schematic diagram of the ratio of right ventricular weight to left ventricular weight (Hilton index) measured after the establishment of the four mouse models in Example 3; Figure 3F is a schematic diagram of pulmonary vascular remodeling detected by hematoxylin and eosin (H&E staining); Figure 3G is a schematic diagram of pulmonary vascular remodeling detected by Masson staining).
[0021] Figure 4 shows a schematic diagram of how tail vein injection of recombinant protein IL-4 reduces pulmonary artery pressure and vascular remodeling in PAH mice (where Figure 4A is a statistical graph of right ventricular systolic pressure; Figure 4B is a statistical graph of the ratio of lung weight to body weight after the establishment of the mouse model; Figure 4C is a schematic diagram of the ratio of heart weight to body weight after the establishment of the mouse model; Figure 4D is a schematic diagram of the ratio of right ventricular weight to left ventricular weight (Hilton index) after the establishment of the mouse model; Figure 4E is a schematic diagram of pulmonary vascular remodeling in each group of mice detected by hematoxylin and eosin (H&Estaining); Figure 4F is a schematic diagram of pulmonary vascular remodeling detected by Masson staining). Detailed Implementation
[0022] To make the purpose, technical solution, and beneficial technical effects of this application clearer, the following detailed description is provided in conjunction with embodiments. It should be understood that the implementation details described in this specification are merely for illustrative purposes and are not intended to limit the scope of this application.
[0023] For simplicity, this application only explicitly discloses some numerical ranges. However, any lower limit can be combined with any upper limit to form a range not explicitly stated; and any lower limit can be combined with other lower limits to form a range not explicitly stated, just as any upper limit can be combined with any other upper limit to form a range not explicitly stated. Furthermore, although not explicitly stated, every point or individual value between the endpoints of the range is included within that range. Therefore, each point or individual value can be used as its own lower or upper limit and combined with any other point or individual value or with other lower or upper limits to form a range not explicitly stated.
[0024] It should be noted that the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Without further limitations, an element defined by the phrase "comprising..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.
[0025] The term "IL-4" refers to interleukin-4, a glycoprotein also known as a pleiotropic cytokine, and is a ligand for the IL-4 receptor.
[0026] The term "IL-4RA" or "IL-4RA protein" refers to the IL-4 receptor α chain (IL-4RA) protein, a transmembrane protein that regulates the activity of immune cells by binding to IL-4 and initiating a series of intracellular signal transduction processes.
[0027] The term "IL-4 / IL-4RA signaling pathway" refers to the expression of IL-4 and IL-4RA proteins in humans or other animals (such as mice), and their interaction with each other to effectively mediate downstream signal transduction and conduct normal IL-4 signaling or IL-4RA signaling. IL-4 is the ligand in the signaling pathway, and IL-4RA is the receptor in the signaling pathway.
[0028] The full English name for the term "pulmonary arterial hypertension" is pulmonary arterial hypertension, abbreviated as PAH.
[0029] The foregoing description of this application is not intended to describe every disclosed implementation or method. Instead, the following description provides more specific examples of exemplary embodiments. Throughout the application, guidance is provided through a series of embodiments, which can be used in various combinations. The examples listed are representative only and should not be construed as exhaustive.
[0030] Pulmonary artery disease, especially peripheral arterial hypertension (PAH), is a serious cardiopulmonary disease characterized by elevated pulmonary artery blood pressure, ultimately leading to right heart failure. The pathogenesis of PAH is complex, involving multiple aspects such as pulmonary vascular smooth muscle cell proliferation, endothelial dysfunction, and immune inflammatory responses. Figure 1 shows decreased IL-4 levels in the peripheral circulation of patients with pulmonary hypertension, indicating a close correlation between IL-4 concentration levels in the body and PAH. Current treatment methods mainly include vasodilators, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors. These drugs can alleviate symptoms and improve hemodynamics to some extent, but they usually cannot fundamentally change the course of the disease, and long-term use is often accompanied by significant side effects such as hypotension and headache.
[0031] In view of the above problems, the inventors have developed a new treatment method for lung diseases by acting on the IL-4 / IL-4RA signaling pathway through a large number of animal experiments.
[0032] A first aspect of this application provides the use of a composition in the preparation of a medicament for the prevention and / or treatment of lung diseases, the composition comprising a substance capable of activating or enhancing the IL-4 / IL-4RA signaling pathway; the lung diseases including pulmonary hypertension, idiopathic pulmonary fibrosis, and asthma.
[0033] Substances that can activate or enhance the IL-4 / IL-4RA signaling pathway primarily address lung diseases, such as pulmonary hypertension, idiopathic pulmonary fibrosis, and asthma, through three main mechanisms: regulating immune responses, inhibiting vascular remodeling, and improving lung function indicators. The prevention and treatment of pulmonary hypertension are particularly important. Regulating immune responses involves modulating the Th2 immune response to inhibit the production of inflammatory cytokines, including but not limited to IL-6 and TNF-α, thereby reducing immune cell infiltration and alleviating lung inflammation. Inhibiting vascular remodeling involves suppressing the proliferation and fibrosis of pulmonary vascular smooth muscle cells through anti-fibrotic effects, preventing abnormal vascular remodeling. Improving lung function refers to improving pulmonary artery pressure and lung function indicators.
[0034] In some embodiments, the substance capable of activating or enhancing the IL-4 / IL-4RA signaling pathway includes at least one of the following: (1) IL-4 protein; (2) a substance that increases the activity and / or content of IL-4 protein; (3) a receptor agonist of IL-4 protein; (4) a substance that increases the activity and / or content of a receptor agonist of IL-4 protein.
[0035] In some embodiments, the IL-4 protein includes at least one of recombinant IL-4 protein, truncated IL-4 protein, mutant IL-4 protein, and fusion IL-4 protein.
[0036] In some embodiments, the IL-4 fusion protein includes at least one of the following: IL-4-Fc fusion protein, IL-4-anti-inflammatory factor fusion protein, and IL-4-targeting peptide fusion protein.
[0037] As an example, in the design of truncated IL-4 proteins, non-essential domains of the IL-4 protein can be removed while retaining its core receptor-binding function, thereby enhancing biological stability and optimizing immunomodulatory function. For instance, some non-critical amino acid residues at the N-terminus or C-terminus of IL-4 can be removed while retaining the IL-4RA receptor binding site, allowing it to still effectively activate the IL-4 signaling pathway, but with a longer serum half-life or higher tissue specificity. Through protein structure analysis, a series of truncated variants can be designed and their affinity and functional properties optimized to ensure their efficacy in PAH treatment. Truncated IL-4 proteins not only improve the stability of the IL-4 protein but also enhance its lung-targeting effect.
[0038] As an example, in the development of IL-4 protein mutants, key residues of the IL-4 protein can be optimized through strategies such as site-directed mutagenesis or directed evolution to improve its stability, receptor affinity, or immunomodulatory capacity. For example: (1) Enhancing the receptor affinity of the IL-4 protein: By mutating key residues of IL-4 at the IL-4RA binding interface, the interaction between the IL-4 protein and its receptor can be improved, enhancing its biological activity and thus achieving the same therapeutic effect at a lower dose. (2) Optimizing the immunomodulatory properties of the IL-4 protein: By mutating key sites affecting the Th2 immune response, such as K77R or Y124D, the immunoreactivity properties of the IL-4 protein can be adjusted, making it more targeted for the treatment of PAH. (3) Enhancing the stability of the IL-4 protein: Through protein engineering optimization, such as introducing stability-enhancing mutations into the IL-4 structure, disulfide rearrangements or misfoldings can be reduced, increasing the protein's half-life in vivo. In IL-4 protein mutants, amino acid substitutions, such as Q116E and R121D, can optimize the binding affinity of IL-4 protein to its receptor and improve its bioefficacy.
[0039] As an example, IL-4 fusion proteins refer to proteins whose pharmacokinetic properties and tissue targeting are improved by fusing the functional domain of IL-4 with other proteins that have immunomodulatory or lung-protective effects.
[0040] Optionally, IL-4-Fc fusion protein refers to the fusion of IL-4 protein with the IgG Fc fragment, thereby increasing the serum half-life of IL-4 protein, increasing the duration of drug efficacy, reducing the frequency of administration, reducing its immunogenicity, and improving treatment stability.
[0041] As an example, the IL-4-anti-inflammatory factor fusion protein can be created by fusing the IL-4 protein with the IL-10 protein, giving it both anti-inflammatory and anti-fibrotic effects, thereby enhancing the treatment efficacy of PAH.
[0042] As an example, IL-4-targeting peptide fusion protein refers to the fusion of IL-4 protein with a pulmonary vascular-specific targeting peptide, thereby enhancing the selective delivery of IL-4 protein in the lungs, reducing systemic side effects, and improving treatment efficacy.
[0043] Optionally, the IL-4 protein includes recombinant IL-4 protein.
[0044] IL-4 protein, as an important immunomodulatory factor, can play a therapeutic role in lung diseases by regulating Th2 immune responses. In the aforementioned lung diseases, excessive inflammation and immune cell infiltration often lead to lung tissue damage and dysfunction. IL-4 protein can not only reduce lung inflammation by inhibiting the production of inflammatory cytokines such as IL-6 and TNF-α, but also further alleviate inflammatory symptoms by reducing immune cell infiltration. Meanwhile, pulmonary vascular remodeling is an important pathological feature of many lung diseases, especially chronic lung diseases such as pulmonary hypertension (PAH). Through its anti-fibrotic effect, IL-4 protein can not only slow down the thickening of the vascular wall by inhibiting the proliferation of pulmonary vascular smooth muscle cells, but also prevent abnormal vascular remodeling by inhibiting the fibrotic process of blood vessels and reducing the deposition of extracellular matrix such as collagen fibers. In addition, IL-4 protein can significantly improve lung function. By activating or enhancing the IL-4 / IL-4RA signaling pathway, IL-4 protein can not only reduce pulmonary artery pressure, but also improve lung function indicators such as vital capacity and maximum expiratory flow, thereby improving patients' respiratory function. It also helps to delay the progression of lung diseases, especially pulmonary hypertension, and improve patients' quality of life and prognosis.
[0045] Optionally, the preparation method of IL-4 protein includes introducing a nucleic acid or vector encoding IL-4 protein into a host cell and then inducing its expression.
[0046] Optionally, the vector encoding the IL-4 protein contains nucleic acid encoding the IL-4 protein.
[0047] Optionally, the vector encoding the IL-4 protein can be expressed in vivo, in vitro, or ex vivo. Preferably, the vector is a prokaryotic expression vector, a viral expression vector, or a eukaryotic expression vector. Examples include E. coli vectors, bacteriophages, etc.
[0048] Alternatively, the host cell can be a eukaryotic cell or a prokaryotic cell.
[0049] As an example, eukaryotic cells include animal and plant cells, such as T cells, yeast cells, HEK293 cells, or CHO cells, etc.
[0050] As an example, prokaryotic cells include Escherichia coli, etc.
[0051] Alternatively, the preparation method of IL-4 protein may also include purification of IL-4 protein using methods such as affinity chromatography or ion exchange chromatography.
[0052] As examples, the sequences of the IL-4 protein include, but are not limited to: NP_067258.1 (Mouse), NP_000580.1 (Human,isoform1), NP_001341919.1 (Human,isoform3), and NP_758858.1 (Human,isoform2).
[0053] In some embodiments, substances that enhance the activity and / or content of IL-4 protein include at least one of proteins, antibodies, antibody mimics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, peptides, peptide mimics, nucleic acid molecules, and small molecule compounds capable of enhancing the activity and / or content of IL-4 protein.
[0054] In some embodiments, substances that enhance IL-4 protein activity and / or content include at least one of gene delivery vectors, protein delivery vectors, nucleic acid molecules, proteins, and fusion proteins capable of enhancing IL-4 protein activity and / or content; optionally, substances that enhance IL-4 protein activity and / or content include at least one of vectors expressing IL-4 protein, mRNA nucleic acid molecules encoding IL-4 protein, lipid nanoparticles carrying the IL-4 gene, viral vectors carrying the IL-4 gene, PEG-modified proteins encapsulating the IL-4 gene or IL-4 protein, protein microspheres encapsulating the IL-4 gene or IL-4 protein, liposomes encapsulating the IL-4 gene or IL-4 protein, and extracellular vesicles encapsulating the IL-4 gene or IL-4 protein; viral vectors include at least one of adeno-associated virus vectors, adenovirus vectors, lentiviral vectors, retroviral vectors, poxvirus vectors, and herpesvirus vectors.
[0055] As an example, the IL-4 gene mentioned above refers to the gene that encodes the IL-4 protein.
[0056] In some embodiments, the receptor agonist of the IL-4 protein includes an agonist of the IL-4RA protein; the agonist of the IL-4RA protein includes at least one of a ligand of the IL-4RA protein, a ligand of a truncated form of the IL-4RA protein, a ligand of a mutant IL-4RA protein, and a ligand of an IL-4RA fusion protein; optionally, the agonist of the IL-4RA protein includes a ligand of the IL-4RA protein.
[0057] Optionally, the IL-4RA protein includes the recombinant IL-4RA protein.
[0058] Optionally, the ligands for the IL-4RA protein include ligands for recombinant IL-4RA protein.
[0059] Optionally, the method for preparing the ligand for the IL-4RA protein includes introducing a nucleic acid or vector encoding the ligand for the IL-4RA protein into a host cell and then inducing its expression.
[0060] Optionally, the vector encoding the ligand of the IL-4RA protein contains nucleic acid encoding the ligand of the IL-4RA protein.
[0061] Optionally, the vector encoding the ligand of the IL-4RA protein can be expressed in vivo, in vitro, or ex vivo. Preferably, the vector is a prokaryotic expression vector, a viral expression vector, or a eukaryotic expression vector. Examples include E. coli vectors, bacteriophages, etc.
[0062] Alternatively, the host cell can be a eukaryotic cell or a prokaryotic cell.
[0063] As an example, eukaryotic cells include animal and plant cells, such as T cells, yeast cells, HEK293 cells, or CHO cells, etc.
[0064] As an example, prokaryotic cells include Escherichia coli, etc.
[0065] Optionally, the preparation method of IL-4RA protein ligands also includes purifying the IL-4RA protein ligands using methods such as affinity chromatography and ion exchange chromatography.
[0066] As examples, the sequences of the IL-4RA protein include, but are not limited to: NP_000409.1 (Human, interleukin-4 receptor subunit alpha isoform a precursor), NP_001244335.1 (Human, interleukin-4 receptor subunit alpha isoform a precursor), NP_001244336.1 (Human, interleukin-4 receptor subunit alpha isoform c), NP_001244926.1 (Human, interleukin-4 receptor subunit alpha isoform d), NP_001008700.1 (Mouse, interleukin-4 receptor subunit alpha isoform 1 precursor), and NP_001350912.1 (Mouse, interleukin-4 receptor subunit alpha isoform 2).
[0067] In some embodiments, substances that enhance the receptor agonist activity and / or content of IL-4 protein include substances capable of enhancing the agonist activity and / or content of IL-4RA protein; optionally, substances that enhance the agonist activity and / or content of IL-4RA protein include at least one of proteins, antibodies, antibody mimics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, peptides, peptide mimics, nucleic acid molecules, and small molecule compounds capable of enhancing the ligand activity and / or content of IL-4RA protein; optionally, substances that enhance the agonist activity and / or content of IL-4RA protein include vectors expressing ligands of IL-4RA protein, mRNA encoding ligands of IL-4RA protein, etc. A. At least one of the following: a nucleic acid molecule, a lipid nanoparticle carrying the ligand gene of the IL-4RA protein, a viral vector carrying the ligand gene of the IL-4RA protein, a PEG-modified protein encapsulating the ligand gene of the IL-4RA protein or the ligand of the IL-4RA protein, a protein microsphere encapsulating the ligand gene of the IL-4RA protein or the ligand of the IL-4RA protein, a liposome encapsulating the ligand gene of the IL-4RA protein or the ligand of the IL-4RA protein, and an extracellular vesicle encapsulating the ligand gene of the IL-4RA protein or the ligand of the IL-4RA protein; the viral vector includes at least one of the following: an adeno-associated virus vector, an adenovirus vector, a lentiviral vector, a retroviral vector, a poxvirus vector, and a herpesvirus vector.
[0068] As an example, the ligand gene of the IL-4RA protein mentioned above refers to the gene that can encode the ligand of the IL-4RA protein.
[0069] In some embodiments, pulmonary hypertension includes at least one of pulmonary arterial hypertension (PAH), pulmonary hypertension caused by chronic obstructive pulmonary disease, and pulmonary hypertension caused by autoimmune disease-related pulmonary vascular disease; optionally, pulmonary hypertension caused by autoimmune disease-related pulmonary vascular disease includes lupus-associated pulmonary hypertension.
[0070] As an example, the lung disease is selected from at least one of pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), asthma, and systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH).
[0071] Alternatively, the lung disease may be pulmonary arterial hypertension (PAH).
[0072] The "medicine" described in this application can be used to treat humans or non-human animals, such as non-human mammals. The medicine may contain pharmaceutically acceptable carriers, excipients, or salts commonly found in the art.
[0073] As an example, the excipients are selected from at least one of diluents, adhesives, lubricants, and wetting agents.
[0074] Optionally, the drug can be in any suitable dosage form, such as a gastrointestinal or non-gastrointestinal dosage form, preferably including but not limited to tablets, pills, powders, granules, capsules, lozenges, syrups, liquids, emulsions, microemulsions, suspensions, injections, sprays, aerosols, powder inhalers, lotions, ointments, plasters, pastes, patches, eye drops, nasal drops, sublingual tablets, suppositories, aerosols, effervescent tablets, pellets, gels, etc. Various dosage forms of the drug can be prepared according to conventional pharmaceutical manufacturing methods.
[0075] As an example, the dosage form of a drug includes at least one of tablets, capsules, granules, suspensions, pellets, injections, and aerosols.
[0076] The drug can be administered via any suitable route of administration, such as gastrointestinal (e.g., oral) or non-gastrointestinal (e.g., intravenous, intramuscular, subcutaneous, intradermal, intra-organ, intranasal, intraocular, intravenous, intracerebral, intrathecal, transdermal, rectal, etc.).
[0077] As an example, routes of drug administration include intravenous injection, subcutaneous injection, or inhalation.
[0078] The drug may contain ligands of the IL-4 protein and IL-4RA protein in a weight ratio of 0.01% to 99.5% (specifically, 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%).
[0079] The dosage of the drug is 180 μg / kg to 1000 μg / kg (e.g., 180 μg / kg, 190 μg / kg, 200 μg / kg, 210 μg / kg, 220 μg / kg, 230 μg / kg, 240 μg / kg, 250 μg / kg, 300 μg / kg, 500 μg / kg, 800 μg / kg, 1000 μg / kg), and may be adjusted according to clinical observation results.
[0080] The use of the compositions of this application in the preparation of medicaments for the prevention and / or treatment of lung diseases, the compositions comprising substances capable of activating or enhancing the IL-4 / IL-4RA signaling pathway, the lung diseases including pulmonary hypertension, idiopathic pulmonary fibrosis and asthma, wherein by activating or enhancing the specific signaling pathway IL-4 / IL-4RA, pulmonary artery pressure can be significantly reduced, vascular remodeling reduced, and inflammatory response inhibited, thereby effectively preventing and / or treating lung diseases, especially pulmonary hypertension (PAH) in pulmonary vascular-related diseases.
[0081] The term "pharmaceutically acceptable" as used in this application refers to the biological activity and characteristics of the active substance in the applied product that neither significantly stimulates the organism nor inhibits it.
[0082] The term "treatment" as used in this application means slowing, interrupting, preventing, controlling, stopping, reducing, or reversing a sign, symptom, disorder, condition, or progression or severity of a disease after it has begun to develop, but does not necessarily involve the complete elimination of all disease-related signs, symptoms, conditions, or disorders.
[0083] The term "prevention" as used in this application refers to a method implemented to prevent or delay the occurrence of a disease, condition, or symptom in the body.
[0084] Example 1: Treatment of PAH mouse model with recombinant IL-4 protein
[0085] (I) The establishment of an animal model includes the following steps:
[0086] S1, animal grouping;
[0087] Healthy C57BL / 6J mice, weighing 20-25g and aged 8-10 weeks, were selected and divided into 4 groups of 8 mice each, as follows:
[0088] Group A: Normal mice + blank control (PBS);
[0089] Group B: PAH mice + blank control (PBS);
[0090] Group C: PAH mice treated with recombinant IL-4 protein.
[0091] S2, the establishment of the PAH model;
[0092] PAH was induced in mice by treating them with a 10% hypoxic environment (10% O2) for 28 days.
[0093] (II) Preparation of recombinant IL-4 protein, specifically including the following steps:
[0094] Commercially available recombinant IL-4 protein (manufacturer: Novaprotein, model: CX88) was used to prepare a 50 μg / mL recombinant IL-4 protein solution with phosphate buffer.
[0095] (III) Experimental methods, specifically including the following steps.
[0096] S1, mice in group C were intravenously injected with recombinant IL-4 protein once every three days for four consecutive weeks;
[0097] S2, mice in group A and group B were intravenously injected with blank control solution PBS every three days for four consecutive weeks;
[0098] S3, mice in groups B and C were placed in a 10% O2 environment to be exposed to hypoxia for 4 weeks to induce PAH;
[0099] S4, Group A was placed in a normal air environment with 21% O2 and cultured for 4 weeks.
[0100] (iv) Detection and analysis, specifically including the following steps.
[0101] S1, pulmonary artery pressure measurement;
[0102] After the experiment, pulmonary artery pressure (mPAP) in mice was measured using right heart catheterization. The therapeutic effect of recombinant IL-4 protein was evaluated by analyzing the changes in pulmonary artery pressure in each group of mice.
[0103] S2, Vascular remodeling assessment;
[0104] Lung tissues from mice in each group were subjected to HE staining, Masson's trichrome staining, and immunohistochemical analysis. The therapeutic effect of recombinant IL-4 protein was evaluated by analyzing pulmonary vessel wall thickness, vascular smooth muscle proliferation, and fibrosis.
[0105] (V) Experimental Results
[0106] 1. Recombinant IL-4 protein can reduce pulmonary artery pressure.
[0107] The average pulmonary artery pressure of mice in group A was 27.26 mmHg, that of mice in group B was 41.24 mmHg, and that of mice in group C was 37.14 mmHg. The pulmonary artery pressure of mice in group B was significantly higher than that of mice in group A; compared with mice in group B, the pulmonary artery pressure of mice in group C was significantly lower.
[0108] 2. Recombinant IL-4 protein can inhibit vascular remodeling.
[0109] 2.1 Recombinant IL-4 protein can reduce the degree of pulmonary vascular smooth muscle proliferation and vascular wall thickness.
[0110] HE staining results showed that, compared with group B, group C mice had significantly reduced pulmonary vascular smooth muscle proliferation and significantly decreased vascular wall thickness.
[0111] 2.2 Recombinant IL-4 protein can reduce collagen deposition in the pulmonary adventitia.
[0112] Masson staining results showed that, compared with group B, group C mice had reduced collagen deposition in the adventitia of pulmonary blood vessels, indicating a reduced fibrosis process and a significantly decreased degree of vascular wall remodeling.
[0113] In summary, recombinant IL-4 protein demonstrated significant therapeutic effects in the PAH mouse model (see Figure 4). Treatment with recombinant IL-4 protein effectively reduced pulmonary artery pressure, alleviated smooth muscle hyperplasia and vascular wall fibrosis in pulmonary vessels, and exhibited good anti-PAH effects.
[0114] Example 2: Experiment of IL-4 gene knockout mouse model in hypoxia-induced PAH
[0115] (I) Establishment and grouping of animal models, specifically including the following steps:
[0116] S1, animal grouping;
[0117] IL-4 gene knockout mice were purchased from Shanghai Southern Model Biotechnology Co., Ltd., catalog number NM-KO-190503.
[0118] Thirty IL-4 gene knockout mice (IL-4- / -) and 30 wild-type mice (WT) were selected, weighing approximately 20-25g and aged 8-10 weeks.
[0119] S2, the establishment of the PAH model;
[0120] PAH model was induced using chronic hypoxia (10% O2) environment method, with continuous exposure for 4 weeks.
[0121] S3, Experimental Groups;
[0122] Group A (Normoxia_WT): Wild-type mice + normal environment;
[0123] Group B (Normoxia_IL-4KO): IL-4 knockout mice + normal environment;
[0124] Group C (Hypoxia_WT): Wild-type mice + hypoxic environment;
[0125] Group D (Hypoxia_IL-4KO): IL-4 knockout mice + hypoxic environment.
[0126] (II) Experimental Methods
[0127] S1, mice from groups A and B were placed in a standard air environment with 21% O2 and cultured for 4 weeks.
[0128] S2, mice in groups C and D were placed in a 10% O2 environment for 4 weeks to induce PAH.
[0129] (III) Detection and analysis, same as in Example 1
[0130] (IV) Experimental Results
[0131] 1. Knocking out the IL-4 gene increases pulmonary artery pressure.
[0132] The measurement results showed that the average pulmonary artery pressure of mice in group A was 27.01 mmHg, that of mice in group B was 26.58 mmHg, that of mice in group C was 38.38 mmHg, and that of mice in group D was 41.81 mmHg. The pulmonary artery pressure of mice in group D was significantly higher than that of mice in groups A, B, and C.
[0133] 2. Knocking out the IL-4 gene promotes angiogenesis.
[0134] 2.1 Knocking out the IL-4 gene increases the degree of pulmonary vascular smooth muscle proliferation and vessel wall thickness.
[0135] See Figure 2F. Compared with groups A, B and C, group D mice showed significantly increased smooth muscle proliferation and vessel wall thickness in the lung vessels, and the degree of fibrosis in the vessel walls was more severe.
[0136] 2.2 Knockout of the IL-4 gene increases collagen deposition in the adventitia of pulmonary blood vessels.
[0137] Referring to Figure 2G, Masson staining showed that compared with groups A, B, and C, group D mice had significant collagen deposition in the adventitia of pulmonary blood vessels, indicating an exacerbation of the fibrotic process.
[0138] In summary, the IL-4 gene knockout mouse model exhibited significant pathological changes during hypoxia-induced PAH, including significantly increased pulmonary artery pressure and significantly aggravated vascular remodeling (see Figure 2).
[0139] Example 3: Experiment of IL-4RA gene knockout mouse model in hypoxia-induced PAH
[0140] (I) Establishment and grouping of animal models, specifically including the following steps:
[0141] S1, animal grouping;
[0142] IL-4RA gene knockout mice were purchased from Cyagen (Suzhou) Biotechnology Co., Ltd., model number S-KO-16195.
[0143] Healthy IL-4RA knockout mice (IL-4RA- / -) and wild-type mice (WT), both with a C57BL / 6J background, weighing 20-25g and aged 8-10 weeks, were selected and grouped as follows:
[0144] Group A (Normoxia_WT; WT control): Wild-type mice were housed in a normoxic (21% O2) environment;
[0145] Group B (Normoxia_IL-4ra; IL-4RA- / - control): IL-4RA knockout mice were housed in a normoxic (21% O2) environment;
[0146] Group C (Hypoxia_WT; WT+ hypoxia exposure): Wild-type mice were exposed to a 10% O2 hypoxia environment for 28 days;
[0147] Group D (Hypoxia_IL-4ra; IL-4RA- / -+ hypoxia exposure): IL-4RA knockout mice were exposed to a 10% O2 hypoxia environment for 28 days.
[0148] (II) Experimental Methods
[0149] S1, mice from groups A and B were placed in a standard air environment with 21% O2 and cultured for 4 weeks.
[0150] S2, mice in groups C and D were placed in a 10% O2 environment for 4 weeks to induce PAH.
[0151] (III) Detection and analysis, same as in Example 1
[0152] (IV) Experimental Results
[0153] 1. Knocking out the IL-4RA gene increases pulmonary artery pressure.
[0154] The average pulmonary artery pressure of each group of mice was measured as follows:
[0155] Group A (Normoxia_WT; WT control): 24.87 mmHg;
[0156] Group B (Normoxia_IL-4ra; IL-4RA- / - control): 26.81 mmHg;
[0157] Group C (Hypoxia_WT; WT + hypoxia): 39.76 mmHg;
[0158] Group D (Hypoxia_IL-4ra; IL-4RA- / -+ hypoxia): 43.09 mmHg.
[0159] It is evident that the pulmonary artery pressure of mice in group D was significantly higher than that in group C, and also much higher than that in groups A and B.
[0160] 2. Knocking out the IL-4RA gene promotes angiogenesis.
[0161] 2.1 Knocking out the IL-4RA gene increases blood vessel wall thickness
[0162] Referring to Figure 3F, HE staining results showed that the pulmonary arteriolar wall thickness of group D mice was significantly increased compared to groups A, B, and C. This indicates that blocking the IL-4 signaling receptor exacerbates vascular remodeling during pulmonary hypertension.
[0163] 2.2 Knocking out the IL-4RA gene increases collagen deposition in the adventitia of pulmonary blood vessels.
[0164] Referring to Figure 3G, Masson staining results show that, compared with groups A, B, and C, mice in group D had significant collagen deposition and a high degree of fibrosis in the adventitia of pulmonary blood vessels.
[0165] In summary, IL-4RA gene knockout significantly promoted increased pulmonary artery pressure and vascular remodeling in PAH mice (see Figure 3). IL-4RA deficiency led to a significant increase in pulmonary artery pressure, abnormal proliferation of vascular smooth muscle cells, and exacerbated fibrosis.
[0166] The above description is merely a specific implementation of this application. Those skilled in the art will clearly understand that, for the sake of convenience and brevity, the specific working process described above can be referred to the corresponding process in the foregoing method embodiments, and will not be repeated here. It should be understood that the protection scope of this application is not limited thereto. Any person skilled in the art can easily conceive of various equivalent modifications or substitutions within the technical scope disclosed in this application, and these modifications or substitutions should all be covered within the protection scope of this application.
Claims
1. The use of a composition in the preparation of a medicament for the prevention and / or treatment of lung diseases, wherein... The composition includes substances capable of activating or enhancing the IL-4 / IL-4RA signaling pathway; The lung diseases mentioned include pulmonary hypertension, idiopathic pulmonary fibrosis, and asthma.
2. The use according to claim 1, wherein, The substance capable of activating or enhancing the IL-4 / IL-4RA signaling pathway includes at least one of the following: (1) IL-4 protein; (2) Substances that increase the activity and / or content of IL-4 protein; (3) IL-4 protein receptor agonists; (4) Substances that increase the receptor agonist activity and / or content of IL-4 protein.
3. Use according to claim 2, wherein, The IL-4 protein includes at least one of the following: recombinant IL-4 protein, truncated IL-4 protein, mutant IL-4 protein, and fusion IL-4 protein.
4. Use according to claim 3, wherein, The IL-4 fusion protein includes at least one of IL-4-Fc fusion protein, IL-4-anti-inflammatory factor fusion protein, and IL-4-targeting peptide fusion protein.
5. The use according to claim 2, wherein, The substances that enhance the activity and / or content of IL-4 protein include at least one of the following: proteins, antibodies, antibody mimics, fusion proteins, protein analogs, gene delivery vectors, protein delivery vectors, peptides, peptide mimics, nucleic acid molecules, and small molecule compounds.
6. The use according to claim 2, wherein, The substances that enhance IL-4 protein activity and / or content include at least one of gene delivery vectors, protein delivery vectors, nucleic acid molecules, proteins, and fusion proteins capable of enhancing IL-4 protein activity and / or content. Optionally, the substance that enhances the activity and / or content of IL-4 protein includes at least one of the following: a vector expressing IL-4 protein, an mRNA nucleic acid molecule encoding IL-4 protein, lipid nanoparticles carrying the IL-4 gene, a viral vector carrying the IL-4 gene, a PEG-modified protein encapsulating the IL-4 gene or IL-4 protein, a protein microsphere encapsulating the IL-4 gene or IL-4 protein, a liposome encapsulating the IL-4 gene or IL-4 protein, and an extracellular vesicle encapsulating the IL-4 gene or IL-4 protein. The viral vector includes at least one of adeno-associated virus vector, adenovirus vector, lentivirus vector, retrovirus vector, poxvirus vector, and herpesvirus vector.
7. The use according to claim 2, wherein, The receptor agonists of the IL-4 protein include agonists of the IL-4RA protein; The IL-4RA protein agonist includes at least one of the following: IL-4RA protein ligand, IL-4RA protein truncated ligand, IL-4RA protein mutant ligand, and IL-4RA fusion protein ligand. Optionally, the agonist of the IL-4RA protein includes a ligand of the IL-4RA protein.
8. The use according to claim 2, wherein, The substances that enhance the receptor agonist activity and / or content of IL-4 protein include substances that can enhance the agonist activity and / or content of IL-4RA protein. Optionally, the substance that enhances the agonist activity and / or content of IL-4RA protein includes at least one of the following: protein, antibody, antibody mimic, fusion protein, protein analog, gene delivery vector, protein delivery vector, polypeptide, peptide mimic, nucleic acid molecule, and small molecule compound. Optionally, the substance that enhances the agonist activity and / or content of IL-4RA protein includes at least one of the following: a vector expressing a ligand of IL-4RA protein; an mRNA nucleic acid molecule encoding a ligand of IL-4RA protein; lipid nanoparticles carrying a ligand gene of IL-4RA protein; a viral vector carrying a ligand gene of IL-4RA protein; a PEG-modified protein encapsulating a ligand gene of IL-4RA protein or a ligand of IL-4RA protein; protein microspheres encapsulating a ligand gene of IL-4RA protein or a ligand of IL-4RA protein; liposomes encapsulating a ligand gene of IL-4RA protein or a ligand of IL-4RA protein; and extracellular vesicles encapsulating a ligand gene of IL-4RA protein or a ligand of IL-4RA protein. The viral vector includes at least one of adeno-associated virus vector, adenovirus vector, lentivirus vector, retrovirus vector, poxvirus vector, and herpesvirus vector.
9. The use according to claim 1, wherein, The pulmonary hypertension includes at least one of arterial pulmonary hypertension, pulmonary hypertension caused by chronic obstructive pulmonary disease, and pulmonary hypertension caused by autoimmune disease-related pulmonary vascular disease. Optionally, the pulmonary hypertension caused by autoimmune disease-related pulmonary vascular lesions includes lupus-related pulmonary hypertension.
10. The use according to claim 1, wherein, The drug may also include pharmaceutically acceptable carriers, excipients or salts; Optionally, the dosage form of the drug includes a gastrointestinal dosage form or a non-gastrointestinal dosage form; Optionally, the route of administration of the drug may include gastrointestinal administration or non-gastrointestinal administration.
